Conclusions
migraine, obesity, overweight or obesity
MIGRAINE, OBESITY
Findings from the current trial brings new evidence to the clinical efficacy of ketogenic diets and strongly suggests that VLCKD represents an effective treatment or co-adjuvant therapy, in combination with pharmacological approaches, for the management of HFEM in patients with overweight or obesity, who are at higher risk of chronicization, compared to general migraine population. VLCKD might represent a valuable treatment tool also as add-on therapy in patients with unsatisfactory response to conventional migraine pharmacological prophylaxis. Further, as obesity is a negative predictor of responsiveness to monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) in patients with chronic migraine, VLCKD could be recommended in patients with elevated BMI values not responding to antiCGRP mAbs [However, future studies are deemed necessary to confirm our findings in larger, long term, multicenter clinical trials.